A Study of LY3015014 in Participants With High Cholesterol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 527 participants.

Also called NCT01890967

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 527 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01890967
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Japan, Netherlands, Poland, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01890967. Randomized; double masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2017-06-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY3015014 in Participants With High Cholesterol
Condition
Hypercholesterolemia
Intervention (Drug)
LY3015014
Intervention (Drug)
Placebo
Intervention (Drug)
Statin
Intervention (Drug)
Ezetimibe
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01890967
Content hash
833d123adfc30b63140275f204d3f1bfa56b5c14fe4cf4161e29e0b6baf555ee